Vaccinex to delist Common Stock from Nasdaq due to decision; stock suspended since Dec 18, 2024.

Unusual Whales
2025.03.19 04:27
On March 7, 2025, Vaccinex, Inc. (OTC: VCNX), a clinical-stage biotechnology company, revealed its plan to delist its common stock from Nasdaq after suspending trading since December 18, 2024. The Company's innovative approach targets neurodegenerative diseases by inhibiting SEMA4D to block astrogliosis and neuroinflammation. Vaccinex notified Nasdaq of its decision to cease trading the Common Stock, valued at $0.0001 per share.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer